The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy

ERDURAN E., AKSOY A., ZAMAN D.

BLOOD COAGULATION & FIBRINOLYSIS, cilt.20, sa.3, ss.215-217, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1097/mbc.0b013e32831d0f69
  • Dergi Adı: BLOOD COAGULATION & FIBRINOLYSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.215-217
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Glanzmann's thrombasthenia is an inherited platelet function disorder caused by quantitative or qualitative defects of the platelet membrane glycoprotein NUMB complex. Activated recombinant factor VII (rFVIIa) has recently been used in the treatment of patients with Glanzmann's thrombasthenia. We report herein a 16-year-old boy with Glanzmann's thrombasthenia who did not respond to conservative treatment for excessive bleeding and hyperfibrinolysis after tonsillectomy and who was successfully treated with rFVIIa. We suggest that rFVIIa at repeated doses of 80-100 mu g/kg may be used effectively in patients with Glanzmann's thrombasthenia having excessive bleeding associated with hyperfibrinolysis after tonsillectomy in addition to tranexamic acid treatment. Blood Coagul Fibrinolysis 20:215-217 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.